Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations include preclinical and translational data reflecting the potency of buloxibutid’s upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trial Vicore also to […]
AlmeeTM is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis (PF). AlmeeTM has shown effectiveness in reducing anxiety symptoms and improving health-related quality of life in the COMPANION study as reported earlier this year, driving a 2.7-point increase in GAD-7 score and a 4.4 improvement in […]
The COMPANION pivotal study met the primary endpoint and demonstrated significantly reduced anxiety in patients with pulmonary fibrosis. AlmeeTM is the first digital therapy to address the psychological symptom burden of living with pulmonary fibrosis. Stockholm, January 4, 2024 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, […]
Stockholm, September 6, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that it will present two posters on its lead program, C21, under development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society […]
Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The European patent protection: • […]
